

# B7-H3 (4lg) /B7-H3b

Catalog # PVGS1808

### **Specification**

## B7-H3 (4lg) /B7-H3b - Product Information

Primary Accession **Species** 

**O5ZPR3-1** 

Human

Sequence Gly27-Thr461

#### **Purity**

#### **Endotoxin Level**

Less than 1EU per  $\mu g$  by the LAL method.

### **Biological Activity**

Immobilized B7-H3 (4lg) /B7-H3b, His & Avi, Human (Cat.No.: Z03888) at 1.0  $\mu$ g/ml (100  $\mu$ l/Well) on the plate can bind Anti-B7-H3 Antibody, hFc Tag

# **Expression System**

**HEK293** 

# **Theoretical Molecular Weight**

49.5 kDa

Formulation Lyophilized from a 0.22 µm filtered solution in PBS, pH 7.4.

#### Reconstitution

It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH<sub>2</sub>0 more than 100  $\mu$ g/ml.

# Storage & Stability


Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

#### B7-H3 (4Ig) /B7-H3b - Additional Information

# **Target Background**

B7-H3, a member of the B7 family of immunomodulatory molecules, is overexpressed in a wide range of solid cancers.B7-H3 binds to activated T cells via an as yet unidentified receptor. In assays using sub-optimal amount so anti-CD3 stimulation, 2Ig-B7-H3 enhances T cell proliferation, T cell interferon-gamma (IFN-gamma) production, and cytotoxic T cells induction.

### B7-H3 (4lg) /B7-H3b - Protein Information





# B7-H3 (4Ig) /B7-H3b - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- <u>Immunofluorescence</u>
- <u>Immunoprecipitation</u>
- Flow Cytomety
- Cell Culture

B7-H3 (4Ig) /B7-H3b - Images